Family Offices Boost Life Sciences Partners’s Over-Subscribed Fifth Fund
Executive Summary
Family offices are increasing their exposure to Europe’s life sciences sector by investing in venture capital funds, including the just-closed over-subscribed fifth fund from Life Sciences Partners.
You may also be interested in...
VC Roundup: Three New Funds Close As Small, Early Financings Bounce Back
Even Series A rounds have been large during recent record-breaking years for biotech venture capital investment, but it looks like smaller financings for early-stage companies may be in the midst of a comeback. With VC firms closing new funds, that raises the question: Will the number of preclinical and Phase I financings increase?
Forbion Closes Third Fund, 'Agnostic' On When To Invest
Forbion Capital Partners has conducted the final closing of its third main fund Forbion Capital Fund III (FCF III), raising a total of €183m. Despite the Netherlands-based venture firm closing its last fund - FCF II - in 2010 when the investment climate was less friendly, Forbion's investment strategy remains much the same. Managing partner Sander Slootweg explains why.
Big Pharma, UK Universities Launch 'Unique' Early Drug Development Fund
AstraZeneca plc, GlaxoSmithKline plc and Johnson & Johnson are investing £30m between them into a new fund aimed at advancing academic therapeutic research from three leading universities.